Humanized IL-6 pathway antagonists, such as tocilizumab (anti-IL-6R) have been used successfully in rheumatoid arthritis, Castleman’s disease and juvenile idiopathic arthritis [94,95,96], and may have a role in SIRS and CRS. The gene discussed is IL6; the disease is systemic inflammatory response syndrome.